Leqvio Cost in New Hampshire 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Leqvio Actually Costs in New Hampshire in 2026

The Novartis wholesale acquisition cost for inclisiran sits at approximately $3,240 per six-month dose, which works out to roughly $540 per month when annualized. At New Hampshire retail pharmacies, cash-pay patients see prices that mirror this list price almost exactly, because no generic or biosimilar exists yet to create downward pressure. Inclisiran received FDA approval in December 2021, and Novartis has maintained pricing without significant changes into 2026.

That number looks alarming on paper. In practice, most commercially insured patients in New Hampshire never pay anywhere near $3,240 per injection because employer-sponsored plans and the Novartis savings program absorb the bulk of that figure. Patients without commercial insurance, particularly those on New Hampshire Medicaid, face a harder road because the state has not added Leqvio to its preferred drug list.

Two doses per year is the standard maintenance schedule after the loading sequence, so the true annual drug cost at list price is approximately $6,480. That is the ceiling, not the typical patient experience.

New Hampshire Medicaid and Leqvio: The Coverage Gap

New Hampshire Medicaid does not cover Leqvio as of 2026. The state's preferred drug list includes high-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and ezetimibe as first-line options for LDL reduction. PCSK9 inhibitors in the monoclonal antibody class, specifically alirocumab (Praluent) and evolocumab (Repatha), have limited coverage with prior authorization, but inclisiran has not cleared that bar in the New Hampshire Medicaid formulary.

This coverage gap affects a meaningful share of the state's high-cardiovascular-risk population. New Hampshire Medicaid enrollment sits near 175,000 individuals, and atherosclerotic cardiovascular disease (ASCVD) is common in that group. For these patients, the realistic options are maximally tolerated statin therapy, ezetimibe, or exploring 503A compounded inclisiran (discussed below).

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD or heterozygous familial hypercholesterolemia who require further LDL-C lowering beyond maximally tolerated statin therapy plus ezetimibe, PCSK9 inhibitors are recommended." Inclisiran falls within this therapeutic class even though its mechanism targets PCSK9 mRNA rather than the protein itself. The guideline endorsement is clinically relevant, but it does not compel a state Medicaid program to pay.

Patients on NH Medicaid should ask their prescribing clinician about a formal prior authorization appeal citing the ACC/AHA recommendation and their specific LDL-C value. Appeals occasionally succeed even when the formulary default is denial.

Commercial Insurance Coverage in New Hampshire

Most major commercial plans operating in New Hampshire, including Anthem Blue Cross Blue Shield of NH, Harvard Pilgrim, and Cigna, list Leqvio as a covered specialty drug, typically on Tier 3 or Tier 4, subject to prior authorization and step therapy. Step therapy almost always requires documented trials of a high-intensity statin and ezetimibe before the plan approves inclisiran.

Prior authorization criteria typically include:

• An LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe
• A confirmed diagnosis of ASCVD or heterozygous familial hypercholesterolemia (HeFH)
• Documentation of statin intolerance if the patient cannot tolerate full-dose statin therapy

After prior authorization clears, the plan's specialty tier copay applies. That copay ranges widely, from $50 per injection at generous plans to $500 or more at high-deductible plans before the deductible is met. The Novartis savings card (EnrollLeqvio program) then layers on top of commercial coverage to reduce the remaining out-of-pocket balance.

Medicare Part B, rather than Part D, covers Leqvio for eligible patients, because inclisiran is administered by a healthcare provider in an office or clinic setting, not self-administered at home. That Part B classification matters. Under Part B, the standard 20% coinsurance applies after the deductible, which translates to roughly $648 per injection at list price before supplemental coverage. Medigap plans (Plan G, Plan N) cover most or all of that coinsurance. Patients with only original Medicare and no Medigap face meaningful out-of-pocket costs.

The Novartis Leqvio Savings Card in New Hampshire

Novartis offers the EnrollLeqvio co-pay assistance program for commercially insured patients. Eligible patients can pay as little as $0 per dose, subject to a per-year savings cap that Novartis updates annually. The program is not available to patients enrolled in any federal or state government health insurance program, including Medicare, Medicaid, TRICARE, or the VA.

The mechanics: the prescribing clinician or their office staff enrolls the patient through the Novartis hub. Novartis bills the commercial plan first, then applies the savings card to whatever the plan does not cover, down to the program's minimum. Patients in New Hampshire can enroll via telehealth practices just as easily as through an in-person cardiology or primary care office, since New Hampshire permits telehealth prescribing of Leqvio.

One practical point that many patients miss: the savings card resets on January 1 each year, and the first injection of the new plan year may briefly bump out-of-pocket costs if the deductible has not been met. Building that calendar awareness into the treatment plan prevents surprises.

Compounded Inclisiran in New Hampshire: Legality and Practical Access

Compounded inclisiran from 503A pharmacies is legally available to New Hampshire patients in 2026. Federal law under 21 U.S.C. 353a governs 503A compounding pharmacies, which operate under state pharmacy board oversight and compound for individual patient prescriptions rather than in bulk for office stock. New Hampshire's Board of Pharmacy recognizes 503A compounding, and patients can receive compounded inclisiran when a licensed prescriber writes a valid patient-specific prescription.

The cost difference is significant. A 503A compounded inclisiran injection can cost near $0 to $150 depending on the pharmacy, compared with the $3,240 Novartis list price per dose. That spread is the reason cash-pay patients and those without coverage, including NH Medicaid enrollees, are increasingly asking about this route.

Three points of caution apply here:

First, compounded inclisiran is not FDA-approved. The active drug substance used in compounding must come from an FDA-registered supplier, but the final compounded product does not go through Novartis's validated manufacturing process or the FDA's approval pathway. Quality and potency can vary between compounders.

Second, inclisiran is not on the FDA's 503A Bulks List or 503B outsourcing facility lists as of mid-2025. Its compounding legality rests on the patient-specific prescription framework rather than on formal agency sanction. Regulatory status could change.

Third, clinical trial evidence for inclisiran's safety and efficacy was built entirely on the Novartis-manufactured branded product. Extrapolating that data to compounded versions requires an assumption of bioequivalence that has not been formally tested.

Patients considering this path should choose a compounding pharmacy that is accredited by PCAB (Pharmacy Compounding Accreditation Board) and ask for a certificate of analysis on every batch. Their prescribing clinician should monitor LDL-C at 3 months to confirm the expected response, which in the branded trials averaged roughly 50% reduction. ORION-10 (N=1,561) found a 52.3% placebo-adjusted LDL-C reduction at Day 510 with inclisiran 284 mg given every 6 months. Absence of that response with compounded product warrants a conversation about switching to branded Leqvio.

Clinical Evidence Underpinning Inclisiran's Use

Understanding why payers and clinicians accept this price point requires a look at what inclisiran actually does in trials. The ORION program provides the core data.

ORION-10 (N=1,561) and ORION-11 (N=1,617), both published in the New England Journal of Medicine in 2020, enrolled patients with ASCVD (ORION-10) or ASCVD plus other high-risk features (ORION-11). Both trials gave inclisiran 284 mg subcutaneously or placebo at Day 1, Day 90, and then every 6 months. The primary endpoint was percentage change in LDL-C from baseline to Day 510.

In ORION-10, inclisiran produced a 52.3% placebo-adjusted reduction in LDL-C (P<0.0001). In ORION-11, the reduction was 49.9% (P<0.0001). Injection-site reactions were the most common adverse event, occurring in roughly 4-5% of inclisiran patients versus 1% of placebo patients. Serious adverse events were balanced between groups. These results support the FDA label indication for adults with primary hyperlipidemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy.

The ORION-4 trial, a cardiovascular outcomes trial with over 15,000 patients, was still accruing events at the time of this writing. ORION-4 data, expected in 2025-2026, may influence future guideline recommendations and, downstream, payer coverage decisions in states like New Hampshire.

Dr. Kausik Ray, one of the principal ORION investigators, noted in a 2020 NEJM editorial context that inclisiran's twice-yearly dosing addresses "the adherence problem that plagues daily oral therapies," a property that makes it attractive in populations where medication persistence is historically low.

How the Dosing Schedule Affects Total Annual Cost

Inclisiran's dosing frequency is a genuine differentiator from daily oral agents and from the monthly injection schedule of alirocumab and evolocumab. The standard sequence is:

• Day 1: first injection (loading dose)
• Month 3 (Day 90): second injection (loading dose)
• Every 6 months thereafter: single maintenance injection

A patient starting in January 2026 receives three injections in year one and two injections in year two and every year after. At Novartis list price, year-one drug cost reaches approximately $9,720 (three doses at $3,240 each). Maintenance years cost approximately $6,480. Commercial insurance and the savings card typically reduce the patient-paid portion well below $1,000 annually for eligible New Hampshire residents.

Telehealth practices in New Hampshire that prescribe Leqvio often coordinate with local infusion centers, primary care offices, or cardiology practices to administer the injections, since the patient cannot self-administer at home under the current prescribing model. That coordination adds time but rarely adds cost beyond the standard office visit copay.

Telehealth Prescribing of Leqvio in New Hampshire

New Hampshire permits telehealth prescribing of Leqvio, meaning a patient does not need to physically visit a cardiologist's office to start therapy. A licensed clinician in New Hampshire can conduct the initial evaluation by video, review the patient's recent lipid panel and medical history, and send the Leqvio prescription to the specialty pharmacy or coordinate with the patient's local clinic for injection administration.

New Hampshire's telehealth statute (RSA 329:1-d) does not impose a separate in-person visit requirement before prescribing, though some commercial plans require documentation of an in-person lipid evaluation within the prior 12 months as part of their prior authorization criteria. Checking the specific plan's PA requirements before the telehealth visit avoids denials.

HealthRX clinicians licensed in New Hampshire can initiate Leqvio therapy via a synchronous video visit, place the prior authorization, and activate the Novartis savings card enrollment in a single appointment for commercially insured patients.

Comparing Inclisiran to Other LDL-Lowering Options Available in New Hampshire

New Hampshire patients who cannot access or afford Leqvio have several alternatives with different cost profiles:

Rosuvastatin 40 mg generic costs approximately $10-20 per month at most New Hampshire pharmacies and reduces LDL-C by roughly 45-50% as monotherapy. Adding generic ezetimibe 10 mg (approximately $15-25 per month) produces an additional 15-20% reduction, for a combined reduction near 60-65% at a total cost under $50/month. The AHA/ACC Guideline on the Treatment of Blood Cholesterol recommends this combination as standard therapy before escalating to PCSK9-targeted agents.

Alirocumab (Praluent) and evolocumab (Repatha), the monoclonal antibody PCSK9 inhibitors, are self-administered monthly or biweekly and have broader Medicaid formulary coverage than inclisiran in some states, though not yet in New Hampshire. Their list prices are comparable to inclisiran's.

Bempedoic acid (Nexletol) and the combination tablet bempedoic acid/ezetimibe (Nexlizet) offer non-statin LDL reduction for statin-intolerant patients at a lower cost than biologics, typically $50-200/month with assistance programs, and are orally administered.

The right choice depends on each patient's LDL-C target, tolerance for injection, insurance coverage, and adherence history. Inclisiran's twice-yearly schedule has the most forgiving adherence profile of any agent in this class.

Steps for a New Hampshire Patient Seeking Leqvio in 2026

Getting Leqvio in New Hampshire is a multi-step process, but the path is well-defined:

1. Obtain a recent lipid panel showing LDL-C at or above target (typically above 70 mg/dL on maximally tolerated statin plus ezetimibe, or above 100 mg/dL in lower-risk populations).
2. Confirm diagnosis of ASCVD or HeFH with the prescribing clinician, since these are the FDA-approved indications.
3. Schedule a telehealth or in-person appointment with a New Hampshire-licensed clinician.
4. The clinician submits a prior authorization to the commercial plan (if applicable) or discusses 503A compounding options for uninsured or NH Medicaid patients.
5. Enroll in the Novartis EnrollLeqvio savings program if commercially insured (not eligible for Medicare/Medicaid).
6. Choose an injection administration site: a local cardiologist, primary care office, or infusion center that can administer subcutaneous injections.
7. Confirm LDL-C response at the 3-month follow-up visit to verify the medication is working as expected.

Patients whose LDL-C does not fall by at least 40% from baseline at the 3-month check should discuss adherence, injection technique, or switching to branded Leqvio if using compounded inclisiran.

What to Expect at Your First Leqvio Injection Appointment

The injection itself takes under two minutes. Inclisiran 284 mg/1.5 mL is drawn up by the clinician or nurse and administered as a subcutaneous injection in the abdomen, upper arm, or thigh. Patients do not need to fast beforehand. A brief observation period of 10-15 minutes is standard practice to monitor for injection-site reactions, which are usually mild erythema or tenderness resolving within 48 hours.

Blood pressure, a current medication list, and kidney function (eGFR) are reviewed at the visit, since the FDA label recommends monitoring in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), though dose adjustment is not currently required. The FDA prescribing information notes no clinically meaningful drug-drug interactions identified with inclisiran, which simplifies polypharmacy management in the typical ASCVD patient on multiple cardiovascular medications.

Schedule the Day 90 follow-up injection before leaving the first appointment. The twice-yearly maintenance cadence is easiest to maintain when the next appointment is already on the calendar.